API | Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant)

Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant) (Comvax) Report issue

Vaccine Approved ^FDA

AACT

Active Ingredient History

NOW

Haemophilus B and hepatitis B vaccine is a combination vaccine whose generic name is Haemophilus b conjugate and hepatitis B recombinant vaccine. It protects against the infectious diseases Haemophilus influenzae type B and hepatitis B. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

comvax | hepb-hib | hib/hep b vaccine

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (2)

Haemophilus Infections (approved 1996)

Hepatitis (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Chickenpox (Phase 3)

Haemophilus influenzae type b (Phase 3)

Hepatitis B (Phase 3)

Measles (Phase 3)

Mumps (Phase 3)

Rotavirus Infections (Phase 3)

Rubella (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue